HK1129277A1 - Tannate salt of rasagiline - Google Patents

Tannate salt of rasagiline

Info

Publication number
HK1129277A1
HK1129277A1 HK09109429.3A HK09109429A HK1129277A1 HK 1129277 A1 HK1129277 A1 HK 1129277A1 HK 09109429 A HK09109429 A HK 09109429A HK 1129277 A1 HK1129277 A1 HK 1129277A1
Authority
HK
Hong Kong
Prior art keywords
rasagiline
tannate salt
tannate
salt
compositions
Prior art date
Application number
HK09109429.3A
Other languages
English (en)
Inventor
Anton Frenkel
Tamas Koltai
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HK1129277A1 publication Critical patent/HK1129277A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
HK09109429.3A 2006-12-14 2009-10-13 Tannate salt of rasagiline HK1129277A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87503806P 2006-12-14 2006-12-14
PCT/US2007/025516 WO2008076315A1 (en) 2006-12-14 2007-12-13 Tannate salt of rasagiline

Publications (1)

Publication Number Publication Date
HK1129277A1 true HK1129277A1 (en) 2009-11-27

Family

ID=39536617

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09109429.3A HK1129277A1 (en) 2006-12-14 2009-10-13 Tannate salt of rasagiline

Country Status (24)

Country Link
US (1) US7547806B2 (da)
EP (1) EP2101570B1 (da)
JP (1) JP5356248B2 (da)
KR (1) KR101077835B1 (da)
CN (1) CN101600346B (da)
AU (1) AU2007334493B2 (da)
BR (1) BRPI0718339A2 (da)
CA (1) CA2672452C (da)
DK (1) DK2101570T3 (da)
EA (1) EA016843B1 (da)
ES (1) ES2420124T3 (da)
HK (1) HK1129277A1 (da)
HR (1) HRP20130396T1 (da)
IL (1) IL198984A (da)
MX (1) MX2009006252A (da)
NO (1) NO20092609L (da)
NZ (1) NZ577623A (da)
PL (1) PL2101570T3 (da)
PT (1) PT2101570E (da)
RS (1) RS52784B (da)
SI (1) SI2101570T1 (da)
UA (1) UA97382C2 (da)
WO (1) WO2008076315A1 (da)
ZA (1) ZA200903904B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005269416B2 (en) * 2004-07-26 2011-07-28 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
PT1848415E (pt) * 2005-02-17 2013-06-27 Teva Pharma Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
AU2006216696B2 (en) 2005-02-23 2011-08-18 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
AU2006316585B2 (en) * 2005-11-17 2012-09-20 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
WO2007098264A2 (en) 2006-02-21 2007-08-30 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
WO2007117431A2 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
ES2375761T3 (es) * 2006-12-14 2012-03-06 Teva Pharmaceutical Industries Ltd. Base de rasagilina cristalina sólida.
NZ577623A (en) 2006-12-14 2011-05-27 Teva Pharma Tannate salt of rasagiline
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
CA2698695A1 (en) * 2007-09-05 2009-03-12 Teva Pharmaceutical Industries Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
AU2009258120B2 (en) * 2008-06-10 2014-11-27 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
EP2296462A4 (en) * 2008-06-13 2011-06-15 Teva Pharma RASAGILINE FOR INFLUENCING MORBUS PARKINSON
JP2011524907A (ja) 2008-06-19 2011-09-08 テバ ファーマシューティカル インダストリーズ リミティド 固体ラサギリン塩基を調製および乾燥する方法
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
JP2012532843A (ja) 2009-07-09 2012-12-20 ラティオファーム ゲーエムベーハー ラサギリンの塩およびその製剤
EP2325159A1 (en) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Novel salts of rasagiline
WO2011087791A1 (en) * 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan
WO2011080589A2 (en) 2009-12-30 2011-07-07 Actavis Group Ptc Ehf Solid state forms of rasagiline salts
WO2011095985A2 (en) * 2010-02-02 2011-08-11 Glenmark Generics Limited Rasagiline salts and processes for the preparation thereof
US8569379B2 (en) 2010-07-27 2013-10-29 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
US8691872B2 (en) 2010-07-27 2014-04-08 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
BR112014008555A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-formil-propargil-aminoindano
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
EP2827848B1 (en) 2012-03-21 2016-04-27 Synthon BV Stabilized pharmaceutical compositions comprising rasagiline salts
BR112015003451A2 (pt) 2012-08-17 2017-07-04 Teva Pharma formulação parentérica de rasagilina
AU2015247921B2 (en) * 2014-04-17 2019-07-11 Merck Sharp & Dohme Llc Sitagliptin tannate complex
CN107125438A (zh) * 2016-02-29 2017-09-05 湖南晶天科技实业有限公司 一种饲料添加剂鞣酸生物碱及其制备方法以及一种复合添加剂和一种饲料
TW201818969A (zh) * 2016-10-19 2018-06-01 日商帝化製藥股份有限公司 在生體內之藥物溶出控制用組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
US5663415A (en) * 1996-06-28 1997-09-02 Jame Fine Chemicals, Inc. Process for preparing antihistamine tannates
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
DE69732984T2 (de) 1996-12-18 2006-02-16 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
FR2771102B1 (fr) * 1997-11-14 2000-12-15 Biocoral Inc Procede pour induire la differenciation osteoblastique de cellules de tissu adipeux extramedullaire humain
WO2002005745A2 (en) * 2000-07-14 2002-01-24 Cadila Pharmaceuticals Limited The process of manufacturing pharmaceutical grade tannates
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US6869618B2 (en) 2001-04-10 2005-03-22 Kiel Laboratories, Inc. Process for preparing tannate liquid and semi-solid dosage forms
AU2003290838A1 (en) * 2002-11-15 2004-06-15 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
US20040157784A1 (en) * 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
WO2004093867A2 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use
WO2005023257A1 (en) * 2003-09-03 2005-03-17 Glaxo Group Limited Novel process, salts, compositions and use
US20050053656A1 (en) * 2003-09-05 2005-03-10 Ping Jeffrey H. Compositions and methods for treating pain
US20050202050A1 (en) * 2004-03-12 2005-09-15 Kiel Jeffrey S. Single tank process for preparing tannate liquid and semi-solid dosage forms
AU2005269416B2 (en) * 2004-07-26 2011-07-28 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
WO2006057912A2 (en) 2004-11-24 2006-06-01 Teva Pharmaceutical Industries, Ltd. Rasagiline orally disintegrating compositions
AU2006216696B2 (en) * 2005-02-23 2011-08-18 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
AU2006316585B2 (en) * 2005-11-17 2012-09-20 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
WO2007098264A2 (en) 2006-02-21 2007-08-30 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
WO2007117431A2 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
NZ577623A (en) 2006-12-14 2011-05-27 Teva Pharma Tannate salt of rasagiline
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff

Also Published As

Publication number Publication date
EA200970580A1 (ru) 2009-12-30
US7547806B2 (en) 2009-06-16
HRP20130396T1 (en) 2013-06-30
AU2007334493B2 (en) 2010-12-02
NZ577623A (en) 2011-05-27
AU2007334493A1 (en) 2008-06-26
JP5356248B2 (ja) 2013-12-04
EP2101570B1 (en) 2013-02-13
JP2010513280A (ja) 2010-04-30
DK2101570T3 (da) 2013-05-27
WO2008076315A1 (en) 2008-06-26
MX2009006252A (es) 2009-10-13
PT2101570E (pt) 2013-05-17
SI2101570T1 (sl) 2013-06-28
KR20090088433A (ko) 2009-08-19
ZA200903904B (en) 2010-08-25
UA97382C2 (ru) 2012-02-10
PL2101570T3 (pl) 2013-07-31
EP2101570A1 (en) 2009-09-23
CN101600346B (zh) 2013-08-21
US20080146676A1 (en) 2008-06-19
CA2672452A1 (en) 2008-06-26
ES2420124T3 (es) 2013-08-22
RS52784B (en) 2013-10-31
EA016843B1 (ru) 2012-07-30
NO20092609L (no) 2009-09-04
IL198984A (en) 2013-03-24
KR101077835B1 (ko) 2011-10-28
CN101600346A (zh) 2009-12-09
CA2672452C (en) 2012-07-03
EP2101570A4 (en) 2011-04-06
BRPI0718339A2 (pt) 2014-02-18
IL198984A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
HK1129277A1 (en) Tannate salt of rasagiline
EG25147A (en) Process for the manufacture of 1,2-dichloroethane.
UA97502C2 (ru) Кристаллическая твердая основа разагилина
DK3872059T3 (en) Process for the preparation of 2,3,3,3 tetrahydrofluoropropene
WO2007093627A3 (de) Biozide zusammensetzung
EG25812A (en) Process for the manufacture of 1,2-dichloroethane
PL1993985T3 (pl) Sposób wytwarzania 1,2-propanodiolu
MX284139B (es) Produccion de isoprenoides.
TW200745261A (en) Aqueous dispersions based on nitrocellulose-polyurethane particles
ZA200904333B (en) Process for the preparation of 6,6-Dimethyl-3-azabicyclo-[3.1.0]-hexane compounds utilizing bisulfite intermediate
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
MX2009004030A (es) Articulos antimicrobianos y metodos de fabricacion.
TW200833649A (en) Method for the preparation of hydroxyadamantanamine
MX2009009490A (es) Profarmacos novedosos.
TW200734339A (en) Forms of dolasetron mesylate and processes for their preparation
TW200637832A (en) Process for preparing amorphous valsartan
WO2008015584A3 (en) Improved process for synthesizing desvenlafaxine free base and salts or solvates thereof
EG25292A (en) Process for the production of anilines.
EP1996192A4 (en) PROCESS FOR PREPARING 3,4-SUBSTITUTED THIAZOLIDIN-2-ONES IN 3,4
IL192153A0 (en) Process for manufacturing entacapone
WO2008090465A3 (en) Process for synthesizing desvenlafaxine free base and salts or salvates thereof
WO2008029267A3 (de) Hydrochloride von 3-amino-2-hydroxycarbonsäureamiden
MX2009003196A (es) Proceso para la preparacion de y-butirolactonas.
EP1915380A4 (en) PROCESS FOR THE SYNTHESIS OF N, N'-DISUBSTITUTED OXABISPIDINES
WO2008038146A3 (en) Improved processes for preparing vanlafaxine base and salts thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161213